Trials / Unknown
UnknownNCT01882946
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Northwest Biotherapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study comprises a Phase I component during which the optimal dose of DCVax-Direct for the treatment of solid tissue tumors will be identified, followed by a Phase II component to determine if the injection of DCVax-Direct into selected solid tissue tumors has the ability to reduce tumor growth.
Conditions
- Locally Advanced Tumor
- Metastatic Solid Tissue Tumors
- Liver Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Melanoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DCVax-Direct | Autologous, activated dendritic cells for intratumoral injection |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2016-12-01
- First posted
- 2013-06-21
- Last updated
- 2015-10-07
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01882946. Inclusion in this directory is not an endorsement.